Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences Conference
Lineage Cell Therapeutics (NYSE American and TASE: LCTX), a clinical-stage biotechnology company focused on developing allogeneic cell therapies for neurological conditions, has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare Lifesciences Conference.
The company's CEO, Brian M. Culley, is scheduled to present on February 11, 2025, at 12:40pm ET. The conference will be held virtually from February 11-12, 2025. Interested parties will be able to access a replay of the presentation through the Events and Presentations section of Lineage's website, with additional video content available on the company's Media page.
Lineage Cell Therapeutics (NYSE American e TASE: LCTX), una azienda biotecnologica in fase clinica che si concentra sullo sviluppo di terapie cellulari allogeniche per condizioni neurologiche, ha annunciato la sua partecipazione alla prossima Oppenheimer 35esima Conferenza Annuale sulle Scienze della Salute.
Il CEO dell'azienda, Brian M. Culley, è programmato per presentare il 11 febbraio 2025, alle 12:40 ET. La conferenza si terrà virtualmente dall'11 al 12 febbraio 2025. Le parti interessate potranno accedere a una registrazione della presentazione attraverso la sezione Eventi e Presentazioni del sito web di Lineage, con contenuti video aggiuntivi disponibili sulla pagina Media dell'azienda.
Lineage Cell Therapeutics (NYSE American y TASE: LCTX), una empresa de biotecnología en etapa clínica centrada en el desarrollo de terapias celulares alogénicas para condiciones neurológicas, ha anunciado su participación en la próxima 35ª Conferencia Anual de Ciencias de la Salud de Oppenheimer.
El CEO de la empresa, Brian M. Culley, está programado para presentar el 11 de febrero de 2025, a las 12:40 p.m. ET. La conferencia se llevará a cabo de forma virtual del 11 al 12 de febrero de 2025. Las partes interesadas podrán acceder a una repetición de la presentación a través de la sección de Eventos y Presentaciones del sitio web de Lineage, con contenido de video adicional disponible en la página de Medios de la empresa.
라인이지 셀 테라퓨틱스 (NYSE American 및 TASE: LCTX), 신경학적 질환을 위한 동종 세포 치료제 개발에 주력하는 임상 단계의 생명공학 회사가 다가오는 오펜하이머 제35회 연례 헬스케어 생명 과학 컨퍼런스에 참여한다고 발표했습니다.
회사의 CEO인 브라이언 M. 컬리(Brian M. Culley)가 2025년 2월 11일 오후 12시 40분 ET에 발표할 예정입니다. 컨퍼런스는 2025년 2월 11일부터 12일까지 가상으로 개최됩니다. 관심 있는 분들은 라인이지 웹사이트의 이벤트 및 발표 섹션을 통해 발표 다시보기 접근이 가능하며, 회사의 미디어 페이지에서 추가 비디오 콘텐츠를 이용할 수 있습니다.
Lineage Cell Therapeutics (NYSE American et TASE : LCTX), une entreprise de biotechnologie en phase clinique axée sur le développement de thérapies cellulaires allogéniques pour les conditions neurologiques, a annoncé sa participation à la prochaine 35e Conférence Annuelle sur les Sciences de la Santé d'Oppenheimer.
Le PDG de l'entreprise, Brian M. Culley, est prévu pour une présentation le 11 février 2025 à 12h40 ET. La conférence se tiendra virtuellement du 11 au 12 février 2025. Les parties intéressées pourront accéder à un enregistrement de la présentation via la section Événements et Présentations du site Web de Lineage, avec un contenu vidéo supplémentaire disponible sur la page Médias de l'entreprise.
Lineage Cell Therapeutics (NYSE American und TASE: LCTX), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von allogenen Zelltherapien für neurologische Erkrankungen konzentriert, hat die Teilnahme an der bevorstehenden 35. Jahreskonferenz für Gesundheitswissenschaften von Oppenheimer bekannt gegeben.
Der CEO des Unternehmens, Brian M. Culley, wird voraussichtlich am 11. Februar 2025 um 12:40 Uhr ET präsentieren. Die Konferenz findet virtuell vom 11. bis 12. Februar 2025 statt. Interessierte Personen haben die Möglichkeit, eine Aufzeichnung der Präsentation über den Bereich Ereignisse und Präsentationen auf der Website von Lineage abzurufen, wobei zusätzliches Videomaterial auf der Medienseite des Unternehmens verfügbar ist.
- None.
- None.
Interested parties can view a replay of the presentation on the Events and Presentations section of Lineage’s website. Additional videos are available on the Media page of the Lineage website.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, “off-the-shelf,” cell therapies to address unmet medical needs. Lineage’s programs are based on its proprietary cell-based technology platform and associated development and manufacturing capabilities. From this platform, Lineage designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions similar or identical to cells found naturally in the human body. These cells are created by applying directed differentiation protocols to established, well-characterized, and self-renewing pluripotent cell lines. These protocols generate cells with characteristics associated with specific and desired developmental lineages. Cells derived from such lineages are transplanted into patients in an effort to replace or support cells that are absent or dysfunctional due to degenerative disease, aging, or traumatic injury, and to restore or augment the patient’s functional activity. Lineage’s neuroscience focused pipeline currently includes: (i) OpRegen®, a retinal pigment epithelial cell therapy in Phase 2a development under a worldwide collaboration with Roche and Genentech, a member of the Roche Group, for the treatment of geographic atrophy secondary to age-related macular degeneration; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of spinal cord injuries; (iii) ReSonance™ (ANP1), an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; (iv) PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and (v) RND1, a novel hypoimmune induced pluripotent stem cell line being developed under a gene editing partnership. For more information, please visit www.lineagecell.com or follow the company on X/Twitter @LineageCell.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250204670950/en/
Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
(ir@lineagecell.com)
(442) 287-8963
Russo Partners – Media Relations
Nic Johnson or David Schull
(Nic.johnson@russopartnersllc.com)
(David.schull@russopartnersllc.com)
(212) 845-4242
Source: Lineage Cell Therapeutics, Inc.
FAQ
When is Lineage Cell Therapeutics (LCTX) presenting at the Oppenheimer Healthcare Conference?
How can investors watch LCTX's Oppenheimer Conference presentation?
What is the duration of the Oppenheimer Healthcare Conference where LCTX is presenting?
What type of therapies is LCTX developing according to the announcement?
